The role of adipocytokines in the development of non-alcoholic fatty liver disease in patients with hypertension and obesity

Yu.M. Yarynych

Abstract


Background. Incidence of non-alcoholic fatty liver disease (NAFLD) is increasing throughout the world along with epidemic of obesity (OB) and type 2 diabetes mellitus. The purpose of the study was to analyze the levels of leptin, adiponectin and leptin resistance in patients with NAFLD and OB. Mate­rials and methods. The study involved 96 patients with NAFLD. The average age of patients was 53.70 ± 5.34 years. Compensated type 2 diabetes mellitus was diagnosed in 44 individuals. Fifty apparently healthy people matched by age and sex (60 % — women, 40 % — men) were included into the control group. Levels of leptin, adiponectin were studied by enzyme-linked immunosorbent assay. Results. It was found that leptin levels are much higher (1.74–2.39 times; p < 0.001) in women than in men, regardless of the type of NAFLD (steatosis or non-alcoholic steatohepatitis (NASH)) and the degrees of OB. In men with steatohepatosis, the concentration of leptin prevailed over that of men with steatohepatitis — by 25.39 % (pNASH < 0.05). Additionally, in the presence of OB degree III, the content of leptin was higher than in OB degrees I and II, regardless of sex. There was an increase in the rate of leptin resistance by 22.22 % (p < 0.05) in steatosis, and by 46.15 % (p = 0.035) and 42.79 % (p = 0.044), respectively, in patients with NAFLD in general and with OB degree III. On the contrary, the concentration of anti-inflammatory adiponectin in OB degrees II and III was lower than in OB degree I by 5.73 and 5.91 % (p < 0.05). Conclusions. The course of NAFLD is accompanied by disorders in the secretory function of adipose tissue, hyperleptinemia, more severe in women, without a clear dependence of steatosis or NASH and the degree of obesity. OB degrees II and III is associated with lower content of adiponectin (p < 0.05).

Keywords


non-alcoholic fatty liver disease; obesity; leptin; adiponectin; leptin resistance

References


European Association for the Study of the Liver (EASL)1; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x.

Ding Y, Li S, Ma RL, et al.Association of homeostasis model assessment of insulin resistance, adiponectin, and low-grade inflammation with the course of the metabolic syndrome. Clin Biochem. 2015 May;48(7-8):503-7. doi: 10.1016/j.clinbiochem.2015.02.005.

Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of literature. J Clin Gastroenterol. 2011 Jan;45(1):50-4. doi: 10.1097/MCG.0b013e3181ec5c66.

Imajo K, Fujita K, Yoneda M, et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signalling. Cell Metab. 2012 Jul 3;16(1):44-54. doi: 10.1016/j.cmet.2012.05.012.

Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: A narrative review. Metabolism. 2015 Jan;64(1):60-78. doi: 10.1016/j.metabol.2014.10.012.

Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism. 2014 Feb;63(2):161-7. doi: 10.1016/j.metabol.2013.10.010.

Polyzos SA, Mantzoros CS. Leptin in health and disease: facts and expectations at its twentieth anniversary. Metabolism. 2015 Jan;64(1):5-12. doi: 10.1016/j.metabol.2014.10.017.

Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995 Nov 10;270(45):26746-9.

Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83.

Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in nash: TNF-α or adiponectin? Hepatology. 2004 Jul;40(1):46-54. doi: 10.1002/hep.20280.

Moschen AR. Molnar C, Wolf AM, et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol. 2009 Oct;51(4):765-77. doi: 10.1016/j.jhep.2009.06.016.

Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism. 2011 Mar;60(3):313-26. doi: 10.1016/j.metabol.2010.09.003.

Ayonrinde OT, Olynyk JK, Beilin LJ, et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology. 2011 Mar;53(3):800-9. doi: 10.1002/hep.24097.

Ministry of Health of Ukraine. Oder No 862, dated Nov 06, 2014: On the approval and implementation of medical and technological documents on the standardization of medical care for chronic non-infectious hepatitis. Available from: http://old.moz.gov.ua/ua/portal/dn_20141106_0826.html. (in Ukrainian).

Kobylyak NM, Savchenyuk OA, Virchenko O, Falalyeyeva TM. Physiopathology role of adiponectine in the development of obesity and associated diseases. World of Medicine and Biology. 2013;(40):81-87. (in Ukrainian).

Sadik NA, Ahmed A, Ahmed S. The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. Hum Exp Toxicol. 2012 Apr;31(4):311-21. doi: 10.1177/0960327111431091.

Hossain IA, Akter S, Rahman MK, Ali L. Gender specific association of serum leptin and insulinemic indices with nonalcoholic fatty liver disease in prediabetic subjects. PLoS One. 2015 Nov 16;10(11):e0142165. doi: 10.1371/journal.pone.0142165.

An BQ, Lu LL, Yuan C, Xin YN, Xuan SY. Leptin receptor gene polymorphisms and the risk of non-alcoholic fatty liver disease and coronary atherosclerosis in the Chinese Han population. Hepat Mon. 2016 Apr 27;16(4):e35055. doi: 10.5812/hepatmon.35055.

Arano T, Nakagawa H, Tateishi R, et al. Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients. Int J Cancer. 2011 Nov 1;129(9):2226-35. doi: 10.1002/ijc.25861.




DOI: https://doi.org/10.22141/2224-0721.14.4.2018.140187

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта